Identification

Name
Zinc sulfate
Accession Number
DB09322
Type
Small Molecule
Groups
Approved, Investigational
Description

Zinc sulfate is the inorganic compound with the formula ZnSO4 as well as any of three hydrates. It was historically known as "white vitriol". All of the various forms are colorless solids. The heptahydrate is commonly encountered. It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.

Structure
Thumb
Synonyms
  • Zinc sulfate (anhydrous)
  • Zinc sulfate anhydrous
  • Zinc sulfate, anhydrous
  • Zinc sulphate anhydrous
  • Zinc sulphate, anhydrous
Product Ingredients
IngredientUNIICASInChI Key
Zinc sulfate heptahydrateN57JI2K7WP7446-20-0RZLVQBNCHSJZPX-UHFFFAOYSA-L
Zinc sulfate hexahydrateNot Available13986-24-8QWCKCWSBAUZZLF-UHFFFAOYSA-L
Zinc sulfate monohydratePTX099XSF17446-19-7RNZCSKGULNFAMC-UHFFFAOYSA-L
Active Moieties
NameKindUNIICASInChI Key
Zinc cationionic13S1S8SF3723713-49-7PTFCDOFLOPIGGS-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Zinc Tally Liq 13.5mg/10mlLiquid13.5 mgOralMetagenics, Inc.1989-12-311996-10-02Canada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Anu-aide - Ont Top 0.5%Ointment.5 %TopicalTechnilab Pharma Inc.1997-07-302005-08-05Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
8-symptom ReliefZinc sulfate (0.25 %) + Tetrahydrozoline hydrochloride (0.05 %)SolutionOphthalmicTeva2016-07-22Not applicableCanada
Allergy Eye DropsZinc sulfate (0.25 %) + Tetrahydrozoline hydrochloride (0.05 %)SolutionOphthalmicTeva2007-05-23Not applicableCanada
Allergy Eye DropsZinc sulfate (0.25 %) + Tetrahydrozoline hydrochloride (0.05 %)SolutionOphthalmicKc Pharmaceuticals, Inc.Not applicableNot applicableCanada
Allergy Eye DropsZinc sulfate (0.25 %) + Tetrahydrozoline hydrochloride (0.05 %)Solution / dropsOphthalmicAlcon, Inc.2005-06-242009-04-24Canada
Anodan-HC 10mg SuppositoriesZinc sulfate (10 mg) + Hydrocortisone acetate (10 mg)SuppositoryRectalOdan Laboratories Ltd1998-08-13Not applicableCanada
Anodan-HC OintmentZinc sulfate (0.5 %) + Hydrocortisone acetate (0.5 %)OintmentRectal; TopicalOdan Laboratories Ltd1995-12-31Not applicableCanada
Anodan-plusZinc sulfate (10 mg) + Pramoxine hydrochloride (20 mg)SuppositoryRectalOdan Laboratories LtdNot applicableNot applicableCanada
Anodan-plus OintmentZinc sulfate (0.5 %) + Pramoxine hydrochloride (1 %)OintmentRectalOdan Laboratories LtdNot applicableNot applicableCanada
Anugesic-HC OintmentZinc sulfate (0.5 %) + Hydrocortisone acetate (0.5 %) + Pramoxine hydrochloride (1 %)OintmentRectalMcneil Consumer Healthcare Division Of Johnson & Johnson Inc1981-12-31Not applicableCanada
Anugesic-HC SuppositoriesZinc sulfate (10 mg) + Hydrocortisone acetate (10 mg) + Pramoxine hydrochloride (20 mg)SuppositoryRectalMcneil Consumer Healthcare Division Of Johnson & Johnson Inc1978-12-31Not applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Multitrace -4Zinc sulfate heptahydrate (22 mg/1mL) + Chromic chloride hexahydrate (51.3 ug/1mL) + Cupric sulfate pentahydrate (3.93 mg/1mL) + Manganese sulfate (1.54 mg/1mL)Injection, solution, concentrateIntravenousAMERICAN REGENT, INC.1993-11-29Not applicableUs
Multitrace -4Zinc sulfate heptahydrate (22 mg/1mL) + Chromic chloride hexahydrate (51.3 ug/1mL) + Cupric sulfate pentahydrate (3.93 mg/1mL) + Manganese sulfate (1.54 mg/1mL)Injection, solution, concentrateIntravenousAMERICAN REGENT, INC.1993-12-07Not applicableUs
Multitrace -4 PediatricZinc sulfate heptahydrate (4.39 mg/1mL) + Chromic chloride hexahydrate (5.12 ug/1mL) + Cupric sulfate pentahydrate (0.4 mg/1mL) + Manganese sulfate (77 ug/1mL)Injection, solution, concentrateIntravenousAMERICAN REGENT, INC.1993-12-09Not applicableUs
Multitrace-4Zinc sulfate heptahydrate (4.39 mg/1mL) + Chromic chloride hexahydrate (20.5 ug/1mL) + Cupric sulfate pentahydrate (1.57 mg/1mL) + Manganese sulfate (0.308 mg/1mL)Injection, solutionIntravenousAMERICAN REGENT, INC.1994-02-17Not applicableUs
Multitrace-4 NeonatalZinc sulfate heptahydrate (6.6 mg/1mL) + Chromic chloride hexahydrate (4.36 ug/1mL) + Cupric sulfate pentahydrate (0.39 mg/1mL) + Manganese sulfate (77 mg/1mL)Injection, solutionIntravenousAMERICAN REGENT, INC.1990-09-30Not applicableUs
Multitrace-5Zinc sulfate heptahydrate (22 mg/1mL) + Chromic chloride hexahydrate (51.3 ug/1mL) + Cupric sulfate pentahydrate (3.93 mg/1mL) + Manganese sulfate (1.54 mg/1mL) + Selenious acid (98 ug/1mL)Injection, solution, concentrateIntravenousAMERICAN REGENT, INC.1993-12-17Not applicableUs
Multitrace-5Zinc sulfate heptahydrate (22 mg/1mL) + Chromic chloride hexahydrate (51.3 ug/1mL) + Cupric sulfate pentahydrate (3.93 mg/1mL) + Manganese sulfate (1.54 mg/1mL) + Selenious acid (98 ug/1mL)Injection, solution, concentrateIntravenousAMERICAN REGENT, INC.1993-09-14Not applicableUs
Multitrace-5Zinc sulfate heptahydrate (4.39 mg/1mL) + Chromic chloride hexahydrate (20.5 ug/1mL) + Cupric sulfate pentahydrate (1.57 mg/1mL) + Manganese sulfate (0.308 mg/1mL) + Selenious acid (32.7 ug/1mL)Injection, solutionIntravenousAMERICAN REGENT, INC.1994-02-17Not applicableUs
Trace Elements 4Zinc sulfate heptahydrate (2.2 mg/1mL) + Chromic chloride hexahydrate (5.12 ug/1mL) + Cupric sulfate pentahydrate (0.4 mg/1mL) + Manganese sulfate (92.3 ug/1mL)Injection, solutionIntravenousAMERICAN REGENT, INC.1994-02-24Not applicableUs
Tricare Prenatal DHA OneZinc sulfate monohydrate (10 mg/1) + Ascorbic acid (60 mg/1) + Biotin (300 ug/1) + Cholecalciferol (800 [iU]/1) + Cupric sulfate (2 mg/1) + Cyanocobalamin (100 ug/1) + Doconexent (215 mg/1) + Docusate sodium (25 mg/1) + Ferrous fumarate (27 mg/1) + Fish oil (500 mg/1) + Folic Acid (1 mg/1) + Icosapent (45 mg/1) + Inositol nicotinate (20 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (3.4 mg/1) + Thiamine mononitrate (3 mg/1) + Vitamin E (30 [iU]/1)Capsule, gelatin coatedOralMedecor Pharma, Llc2012-01-01Not applicableUs
Categories
UNII
0J6Z13X3WO
CAS number
7733-02-0
Weight
Average: 161.472
Monoisotopic: 159.880875756
Chemical Formula
O4SZn
InChI Key
NWONKYPBYAMBJT-UHFFFAOYSA-L
InChI
InChI=1S/H2O4S.Zn/c1-5(2,3)4;/h(H2,1,2,3,4);/q;+2/p-2
IUPAC Name
zinc(2+) ion sulfate
SMILES
[Zn++].[O-]S([O-])(=O)=O

Pharmacology

Indication

This medication is a mineral used to treat or prevent low levels of zinc. In medicine it is used together with oral rehydration therapy (ORT) and an astringent. Zinc Sulfate Injection, USP is indicated for use as a supplement to intravenous solutions given for TPN.

Associated Therapies
Pharmacodynamics

Zinc has been identified as a cofactor for over 70 different enzymes, including alkaline phosphatase, lactic dehydrogenase and both RNA and DNA polymerase. Zinc facilitates wound healing, helps maintain normal growth rates, normal skin hydration and the senses of taste and smell.

Mechanism of action

Zinc inhibits cAMP-induced, chloride-dependent fluid secretion by inhibiting basolateral potassium (K) channels, in in-vitro studies with rat ileum. This study has also shown the specificity of Zn to cAMP-activated K channels, because zinc did not block the calcium (Ca)-mediated K channels. As this study was not performed in Zn-deficient animals, it provides evidence that Zn is probably effective in the absence of Zn deficiency. Zinc also improves the absorption of water and electrolytes, improves regeneration of the intestinal epithelium, increases the levels of brush border enzymes, and enhances the immune response, allowing for a better clearance of the pathogens.

Absorption

Approximately 20 to 30% of dietary zinc is absorbed, primarily from the duodenum and ileum. The amount absorbed is dependent on the bioavailability from food. Zinc is the most bioavailable from red meat and oysters. Phytates may impair absorption by chelation and formation of insoluble complexes at an alkaline pH. After absorption, zinc is bound in the intestine to the protein metallothionein. Endogenous zinc can be reabsorbed in the ileum and colon, creating an enteropancreatic circulation of zinc.

Volume of distribution

After absorption zinc is bound to protein metallothionein in the intestines. Zinc is widely distributed throughout the body. It is primarily stored in RBCs, WBCs, muscles, bones, Skin, Kidneys, Liver, Pancreas, retina, and prostate.

Protein binding

Zinc is 60% bound to albumin; 30 to 40% bound to alpha-2 macroglobulin or transferrin; and 1% bound to amino acids, primarily histidine and cysteine.

Metabolism
Not Available
Route of elimination

Primarily fecal (approximately 90%); to a lesser extent in the urine and in perspiration.

Half life

3 hours

Clearance
Not Available
Toxicity

Human : TDLo ( Oral) 45mg/kg/7D-C : Normocytic anemia, pulse rate increase without fall inBP Human: TDLo (oral) 106mg/kg : Hypermotylity, diarrhea Mouse ; LD50 Oral : 245mg/kg Mouse : LD50 : subcutaneous : 781mg/kg

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
CarbamazepineZinc sulfate can cause a decrease in the absorption of Carbamazepine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CeftibutenZinc sulfate can cause a decrease in the absorption of Ceftibuten resulting in a reduced serum concentration and potentially a decrease in efficacy.
CephalexinZinc sulfate can cause a decrease in the absorption of Cephalexin resulting in a reduced serum concentration and potentially a decrease in efficacy.
CinoxacinZinc sulfate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiprofloxacinZinc sulfate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClomocyclineZinc sulfate can cause a decrease in the absorption of Clomocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DeferiproneZinc sulfate can cause a decrease in the absorption of Deferiprone resulting in a reduced serum concentration and potentially a decrease in efficacy.
DelafloxacinZinc sulfate can cause a decrease in the absorption of Delafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DemeclocyclineZinc sulfate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DifloxacinZinc sulfate can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Food Interactions
Not Available

References

General References
  1. DRUGS.COM [Link]
  2. NCBI [Link]
  3. ChemIDplus [Link]
  4. Wikipedia [Link]
  5. WebMD [Link]
  6. Pubchem [Link]
  7. DAILYMED [Link]
External Links
PubChem Compound
24424
PubChem Substance
310265204
ChemSpider
22833
ChEBI
35176
ChEMBL
CHEMBL1200929
PharmGKB
PA451971
Wikipedia
Zinc_sulfate
ATC Codes
A12CB01 — Zinc sulfateC05AX04 — Zinc preparations
AHFS Codes
  • 88:29.00* — Minerals
  • 84:92.00 — Misc. Skin and Mucous Membrane Agents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentChildren, Only / Pneumonia1
1, 2CompletedNot AvailablePediatric Critical Illness1
2CompletedTreatmentTinnitus1
2Unknown StatusTreatmentAcute Watery Diarrhoea1
2, 3CompletedTreatmentAcute Alcoholic Hepatitis1
2, 3CompletedTreatmentMucositis / Transplantation, Bone Marrow1
3CompletedTreatmentParents2
3RecruitingTreatmentWarts1
4CompletedTreatmentAcute Diarrhoea / Acute Gastroenteritis1
Not AvailableCompletedBasic SciencePoliomyelitis1
Not AvailableCompletedPreventionSevere or persistent diarrhea1
Not AvailableCompletedTreatmentGastroenteritis / Severe or persistent diarrhea1
Not AvailableTerminatedTreatmentRosaceas1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionOphthalmic
SuppositoryRectal
OintmentRectal; Topical
OintmentTopical.5 %
SprayTopical
LiquidTopical
Injection, solution, concentrateIntravenous
Injection, solutionIntravenous
OintmentRectal
OintmentTopical
EmulsionIntravenous
TabletOral
Capsule, gelatin coatedOral
Solution / dropsOphthalmic
Injection, solutionIntravenous1 mg/1mL
Injection, solutionIntravenous5 mg/1mL
LiquidOral13.5 mg
LiquidOphthalmic
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-0.84ChemAxon
pKa (Strongest Acidic)-3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area80.26 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity11.53 m3·mol-1ChemAxon
Polarizability5.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as transition metal sulfates. These are inorganic compounds in which the largest oxoanion is sulfate, and in which the heaviest atom not in an oxoanion is a transition metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Transition metal oxoanionic compounds
Sub Class
Transition metal sulfates
Direct Parent
Transition metal sulfates
Alternative Parents
Inorganic salts / Inorganic oxides
Substituents
Transition metal sulfate / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
zinc molecular entity, metal sulfate (CHEBI:35176)

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Cofactor
General Function
Metal ion binding
Specific Function
Not Available
Gene Name
ALPPL2
Uniprot ID
P10696
Uniprot Name
Alkaline phosphatase, placental-like
Molecular Weight
57376.515 Da
References
  1. DAILYMED [Link]

Drug created on November 17, 2015 10:46 / Updated on December 10, 2018 13:39